Related Experiment Video

Updated: Jun 3, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures

Paul Harmatz1

  • 1Children's Hospital and Research Center Oakland, Oakland, CA, USA.

The Turkish Journal of Pediatrics
|March 26, 2011
PubMed

Insights

Enzyme replacement therapy (ERT) with galsulfase effectively treats Mucopolysaccharidosis VI (MPS VI), a genetic disorder. Clinical trials demonstrate the safety and efficacy of galsulfase in managing this lysosomal storage disease.

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Mucopolysaccharidosis VI (MPS VI) is an inheritable, heterogeneous lysosomal storage disorder.
  • It results from a deficiency in the arylsulfatase B (ASB) enzyme, impairing glycosaminoglycan (GAG) degradation.
  • Accumulation of partially degraded GAGs causes widespread tissue and organ damage.

Purpose of the Study:

  • To provide an overview of clinical trials evaluating galsulfase therapy for MPS VI.
  • To assess the efficacy and safety of enzyme replacement therapy (ERT) with galsulfase.
  • To discuss the outcomes of these clinical trials in MPS VI patients.

Main Methods:

  • Review of clinical trials assessing galsulfase efficacy and safety.
  • Analysis of patient outcomes in trials for Mucopolysaccharidosis VI.
  • Synthesis of data from studies on human recombinant ASB (galsulfase) treatment.

Main Results:

  • Clinical trials have evaluated the efficacy of galsulfase in MPS VI patients.
  • Safety data from these trials indicate a favorable profile for galsulfase.
  • The outcomes suggest that ERT with galsulfase is a viable treatment option.

Conclusions:

  • Enzyme replacement therapy with galsulfase is a promising treatment for MPS VI.
  • Galsulfase demonstrates efficacy in managing the clinical manifestations of MPS VI.
  • Further research and long-term monitoring are essential for optimizing galsulfase therapy.

More Related Videos

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Proteoglycans01:05

Proteoglycans

Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
Glycosaminoglycans01:23

Glycosaminoglycans

Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are long and linear polymers comprising of specific repeating disaccharides - the amino sugar that can be N-acetylglucosamine or N-acetylgalactosamine, and a uronic acid that is usually glucuronic acid or iduronic acid.
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...